Smsbiotech Inc. has gained clearance in Australia to begin a phase I trial of its small mobile stem (SMS) cell therapy for chronic obstructive pulmonary disease (COPD).

MELBOURNE, Australia, August 21, 2025--(BUSINESS WIRE)--SMSbiotech, a San Diego–based leader in regenerative medicine, today announced the initiation of its first-in-human Phase 1 clinical trial for ...

Standardized Stem Cell Care Delivers Measurable, Affordable, and Life-Changing Results Across the U.S. DALLAS, Oct. 22, 2025 /PRNewswire/ -- Life Sciences Review has recognized Innovations Stem Cell ...

This development marks a crucial step forward in SMSbiotech's efforts to address this debilitating respiratory condition. The Phase I trial, conducted in Australia, will be the first human trial of ...

On July 11, 2025, at Veritus Research in Melbourne, Australia, the first dose of SMSbiotech’s novel therapeutic candidate was administered to the inaugural patient. The Phase 1 study, titled “A study ...